Long-term outcomes of avelumab maintenance in older patients with advanced urothelial carcinoma in Japan from the JAVEMACS study
Year: 2026
Type: article
Abstract: The retrospective JAVEMACS chart review study described outcomes of avelumab first-line maintenance for patients with locally advanced/metastatic urothelial carcinoma without progression after platinum-based chemotherapy (PBC) in Japanese real-world practice. This post hoc exploratory analysis compared outcomes by age at avelumab initiation (<75 vs. ≥75 [main] and <80 vs. ≥80 years [supportive]). Stabilized inverse probability of treatment weighting estimated covariate-standardized associations; causal inference was not intended. Overall survival (OS) and progression-free survival (PFS) were assessed using unadjusted and weighted Kaplan-Meier and Cox models. Among 349 patients, 206 (59.0%) and 143 (41.0%) were <75 and ≥75 years, respectively. In the complete-case propensity score analysis set (n = 267), balance improved for most covariates, but some residual imbalance remained and overlap was limited. In the main weighted analyses, there were no statistically significant age-group differences in OS (HR 0.832, 95% CI 0.554–1.248; p = 0.372) and PFS (HR 0.794, 95% CI 0.577–1.093; p = 0.156); supportive results were also not statistically significant. These exploratory observations do not establish equivalence or an age-specific treatment effect, and interpretations should consider the retrospective design, complete-case weighting, limited overlap, and residual confounding. These findings provide descriptive long-term outcomes for older patients receiving avelumab maintenance in Japanese practice.
Source: Scientific Reports
Authors: Suguru Shirotake, Takashi Kobayashi, Yuki Endo, Masaomi Ikeda, Kan Yonemori, Norihiko Kawamura, Takashige Abe, Atsuko Fujihara, Masayoshi Nagata, Kiyohide Fujimoto, Tohru Nakagawa, Shingo Hatakeyama, Kiyoaki Nishihara, Toru Sakatani, Daiki Ikarashi, Naoya Masumori, Sei Naito, Kazutoshi Fujita, Nozomi Hayakawa, Takuto Hara, Noriyoshi Miura, Takahito Negishi, Junji Yatsuda, Naotaka Nishiyama, Rikiya Taoka, Mizuki Kobayashi, Junya Furukawa, Michihiro Shono, Hiroshi Kitamura, Eiji Kikuchi
Institutions: Saitama International Medical Center, Saitama Medical University, Kyoto University, Nippon Medical School Hospital, Kitasato University, National Cancer Center Hospital, Osaka International Cancer Institute, Hokkaido University, Kyoto Prefectural University of Medicine, Juntendo University, Nara Medical University, Teikyo University, Hirosaki University, Kurume University, Iwate Medical University, Sapporo Medical University, Yamagata University, Kindai University, St. Marianna University School of Medicine, Kobe University, Ehime University, National Hospital Organization Kyushu Cancer Center, Kumamoto University, University of Toyama, Kagawa University, Akita University, Tokushima University, Merck Biopharma Co., Ltd. (Japan)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
Funder: Merck KGaA
OpenAlex ID: W7237258644
